Assessment of prognostic risk of death in patients with multiple myeloma based on CD184 and CD269: A retrospective analysis.

IF 1.5 4区医学 Q4 BIOCHEMISTRY & MOLECULAR BIOLOGY

Journal of Medical Biochemistry Pub Date : 2025-09-05 DOI:10.5937/jomb0-56987

Hong Chen, Yuan Zhao, Zhiyu Zhang, Yan Xie, Mulan Jin

{"title":"Assessment of prognostic risk of death in patients with multiple myeloma based on CD184 and CD269: A retrospective analysis.","authors":"Hong Chen, Yuan Zhao, Zhiyu Zhang, Yan Xie, Mulan Jin","doi":"10.5937/jomb0-56987","DOIUrl":null,"url":null,"abstract":"Background: This study aimed to analyze the expressions of CD184 and CD269 in patients with newly diagnosed multiple myeloma (MM) in China and explored their potential association with prognosis.Methods: This retrospective study recruited 100 patients with MM and 113 healthy controls who attended Beijing Chaoyang Hospital Shijingshan District between June 2020 and December 2023. The association between CD184 and CD269 expression and patient survival outcomes was assessed using univariable and multivariable Cox proportional hazards regression analyses, alongside Kaplan-Meier survival curves.Results: Both CD184 and CD269 mRNA were elevated in MM patients compared to controls (P<0.05). By qualitative analysis, it was seen that both CD184+ and CD269 patients had a reduced prognostic overall survival (OS) (P<0.05). Similarly, detection of CD184 and CD269 expression was effective in predicting prognostic mortality in patients.Conclusions: CD184 and CD269 may serve as valuable prognostic markers in MM patients.","PeriodicalId":16175,"journal":{"name":"Journal of Medical Biochemistry","volume":"44 6","pages":"1210-1218"},"PeriodicalIF":1.5000,"publicationDate":"2025-09-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12497470/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Medical Biochemistry","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.5937/jomb0-56987","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"BIOCHEMISTRY & MOLECULAR BIOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Background: This study aimed to analyze the expressions of CD184 and CD269 in patients with newly diagnosed multiple myeloma (MM) in China and explored their potential association with prognosis.

Methods: This retrospective study recruited 100 patients with MM and 113 healthy controls who attended Beijing Chaoyang Hospital Shijingshan District between June 2020 and December 2023. The association between CD184 and CD269 expression and patient survival outcomes was assessed using univariable and multivariable Cox proportional hazards regression analyses, alongside Kaplan-Meier survival curves.

Results: Both CD184 and CD269 mRNA were elevated in MM patients compared to controls (P<0.05). By qualitative analysis, it was seen that both CD184+ and CD269 patients had a reduced prognostic overall survival (OS) (P<0.05). Similarly, detection of CD184 and CD269 expression was effective in predicting prognostic mortality in patients.

Conclusions: CD184 and CD269 may serve as valuable prognostic markers in MM patients.

Abstract Image

查看原文本刊更多论文

基于CD184和CD269的多发性骨髓瘤患者预后死亡风险评估：回顾性分析

背景：本研究旨在分析CD184和CD269在中国新诊断多发性骨髓瘤（MM）患者中的表达，并探讨其与预后的潜在关系。方法：本回顾性研究招募了2020年6月至2023年12月在北京市石景山区朝阳医院就诊的100例MM患者和113例健康对照。通过单变量和多变量Cox比例风险回归分析以及Kaplan-Meier生存曲线，评估CD184和CD269表达与患者生存结果之间的关系。结果：与对照组相比，MM患者的CD184和CD269 mRNA均升高(结论：CD184和CD269可能是MM患者有价值的预后标志物。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Journal of Medical Biochemistry BIOCHEMISTRY & MOLECULAR BIOLOGY-

CiteScore

3.00

自引率

12.00%

发文量

审稿时长

>12 weeks

期刊介绍： The JOURNAL OF MEDICAL BIOCHEMISTRY (J MED BIOCHEM) is the official journal of the Society of Medical Biochemists of Serbia with international peer-review. Papers are independently reviewed by at least two reviewers selected by the Editors as Blind Peer Reviews. The Journal of Medical Biochemistry is published quarterly. The Journal publishes original scientific and specialized articles on all aspects of clinical and medical biochemistry, molecular medicine, clinical hematology and coagulation, clinical immunology and autoimmunity, clinical microbiology, virology, clinical genomics and molecular biology, genetic epidemiology, drug measurement, evaluation of diagnostic markers, new reagents and laboratory equipment, reference materials and methods, reference values, laboratory organization, automation, quality control, clinical metrology, all related scientific disciplines where chemistry, biochemistry, molecular biology and immunochemistry deal with the study of normal and pathologic processes in human beings.